Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 2, Pages 155-160Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543784.2017.1275562
Keywords
Analgesia; pain; delta opioid receptor; opioids
Categories
Funding
- Bundesministerium fur Bildung und Forschung [VIP0272/03V0364, 01EC1403E/F]
- European Commission [EU FP7-602891-2]
- Helmholtz Gemeinschaft
Ask authors/readers for more resources
Introduction: Opioids are widely used to treat severe pain. Most clinically used opioids activate mu-opioid receptors (MOR). Their ligands induce potent analgesia but also adverse effects. The -opioid receptor (DOR) is another member of the opioid receptor family that has been under intense investigation with the aim to avoid MOR-induced side effects.Areas covered: This article reviews DOR ligands which appeared to be promising after preclinical evaluation. A literature search using Pubmed, Cochrane library, ClinicalTrials.gov, EudraCT, AdisInsight database and EBSCO Online Library was conducted. Out of numerous newly synthesized molecules, only few candidates entered phase I and/or II clinical investigation. The publicly accessible results are presented here.Expert opinion: Many compounds showed potent DOR-specific pain inhibition in preclinical studies. ADL5859 and ADL5747 entered clinical trials and successfully passed phase I. However, in phase II studies the primary endpoint (pain reduction) was not met and further investigation was terminated. A third compound, NP2, is in phase II clinical evaluation and results are pending. These findings suggest a potential of DOR ligands according to preclinical studies. Further clinical research and secondary analysis of unpublished data is needed to identify molecules which are useful in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available